Compare Keysight Technologies Inc (KEYS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Neurocrine Biosciences Inc — how do they compare? Keysight Technologies Inc trades at $325.93 (market cap $53.68B), while Neurocrine Biosciences Inc trades at $177.76 (market cap $17.40B). The key difference: Keysight Technologies Inc is far larger — about 3.1× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| KEYS | NBIX | |
|---|---|---|
Market Cap | $53.68B | $17.40B |
Sector | Technology | Health |
52-Week High | $373.34 | $180.55 |
52-Week Low | $158.51 | $123.10 |
Enterprise Value | $54.03B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $313.97, down 0.61% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong profitability with a 17.31% net margin and has secured strategic partnerships, including a European Space Agency contract for 5G network development announced July 15, 2026. Analyst consensus remains strongly bullish with an $396.56 price target, though valuation multiples appear elevated with a P/E of 50.87.
KEYS presents a growth opportunity driven by AI and 5G testing demand, but faces risks from high valuation and volatile cash flows. The stock's near-term direction hinges on Q2 2026 earnings versus the $2.46 EPS estimate, with support at $309 critical for maintaining bullish technical structure.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
